Cargando…

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome

Chimeric antigen receptor (CAR) T cells brought substantial benefit to patients with B‐cell malignancies. Notwithstanding, CAR T‐cell manufacturing requires complex procedures impeding the broad supply chain. Here, we provide evidence that human CD19‐CAR T cells can be generated directly in vivo usi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pfeiffer, Anett, Thalheimer, Frederic B, Hartmann, Sylvia, Frank, Annika M, Bender, Ruben R, Danisch, Simon, Costa, Caroline, Wels, Winfried S, Modlich, Ute, Stripecke, Renata, Verhoeyen, Els, Buchholz, Christian J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220327/ https://www.ncbi.nlm.nih.gov/pubmed/30224381 http://dx.doi.org/10.15252/emmm.201809158

Ejemplares similares

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
por: Krug, Adrien, et al.
Publicado: (2021)

In vivo generated human CAR T cells eradicate tumor cells
por: Agarwal, Shiwani, et al.
Publicado: (2019)

High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia
por: Müller, Stephan, et al.
Publicado: (2020)

In vivo generation of CAR T cells in the presence of human myeloid cells
por: Ho, Naphang, et al.
Publicado: (2022)

Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics
por: Charitidis, Filippos T., et al.
Publicado: (2021)

Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics
por: Charitidis, Filippos T., et al.
Publicado: (2022)

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
por: Bachiller, Mireia, et al.
Publicado: (2021)

Innate-like NKp30(+)CD8(+) T cells armed with TCR/CAR target tumor heterogeneity
por: Correia, Margareta P., et al.
Publicado: (2021)

Advantages and applications of CAR-expressing natural killer cells
por: Glienke, Wolfgang, et al.
Publicado: (2015)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4
por: Jamali, Arezoo, et al.
Publicado: (2020)

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma
por: Merker, Michael, et al.
Publicado: (2020)

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
por: Burger, Michael C., et al.
Publicado: (2019)

CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity
por: Gupta, Sasha, et al.
Publicado: (2023)

Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children
por: Merker, Michael, et al.
Publicado: (2017)

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing
por: Wagner, Dimitrios L., et al.
Publicado: (2022)

The making and function of CAR cells
por: Zabel, Maja, et al.
Publicado: (2019)

Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts
por: Hartmann, Jessica, et al.
Publicado: (2017)

Co-Expression of an IL-15 Superagonist Facilitates Self-Enrichment of GD(2)-Targeted CAR-NK Cells and Mediates Potent Cell Killing in the Absence of IL-2
por: Bodden, Malena, et al.
Publicado: (2023)

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
por: Zhang, Congcong, et al.
Publicado: (2021)

Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer
por: Murali Shankar, Nivedha, et al.
Publicado: (2023)

Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
por: Viaud, Sophie, et al.
Publicado: (2018)

Dasatinib is a potent enhancer for CAR T cell generation by CD3-targeted lentiviral vectors
por: Braun, Angela H., et al.
Publicado: (2022)

B cell depletion and signs of sepsis-acquired immunodeficiency in bone marrow and spleen of COVID-19 deceased
por: Ihlow, Jana, et al.
Publicado: (2021)

CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease
por: Slabik, Constanze, et al.
Publicado: (2020)

Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy
por: Gutierrez-Guerrero, Alejandra, et al.
Publicado: (2020)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies
por: Zhang, Chaoting, et al.
Publicado: (2020)

Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells
por: Pincha, M, et al.
Publicado: (2011)

Adult and Cord Blood-Derived High-Affinity gB-CAR-T Cells Effectively React Against Human Cytomegalovirus Infections
por: Olbrich, Henning, et al.
Publicado: (2020)

CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
por: Kneissl, Sabrina, et al.
Publicado: (2013)

Lentivirus-Induced Dendritic Cells (iDC) for Immune-Regenerative Therapies in Cancer and Stem Cell Transplantation
por: Stripecke, Renata
Publicado: (2014)

Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy
por: Das, Shipra, et al.
Publicado: (2023)

Forming megakaryocytes from murine induced pluripotent stem cells by the inducible overexpression of supporting factors
por: Cullmann, Katharina, et al.
Publicado: (2020)

Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model
por: Singh, Aman P., et al.
Publicado: (2019)

GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies
por: Zhang, Xi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4apsaspgcq90na725uur98nfp8